SGHT
BEARISH
$4.09
Live
Sight Sciences, Inc. · NASDAQ
Target $8.34
(+103.9%)
$2.51
52W Range
$9.24
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 19, 2026
Market cap
$220.88M
P/E
N/A
ROE
-50.7%
Profit margin
-49.7%
Debt/Equity
0.64
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
SGHT exhibits significant fundamental weakness, highlighted by a Piotroski F-Score of 3/9, placing it firmly in the 'Weak' health category. While the company maintains an exceptionally strong liquidity position (Current Ratio of 10.22) and impressive gross margins (86.17%), these are offset by deep negative profit margins and a lack of meaningful revenue growth (6.9% YoY). The bearish outlook is further solidified by aggressive insider selling across the C-suite and a 0/100 technical trend score, suggesting that the analyst target of $8.34 is disconnected from current internal sentiment and financial health.
Key Strengths
Exceptional liquidity with a Current Ratio of 10.22
Very high Gross Margin of 86.17% indicating strong product pricing power
Positive trend in EPS growth (+65.2% YoY) and consistent earnings beats
Manageable Debt/Equity ratio of 0.64
Strong analyst support with a mean target price of $8.34
Key Risks
Weak Piotroski F-Score (3/9) indicating deteriorating fundamental health
Severe negative profit margins (-49.67%) and ROE (-50.74%)
Stagnant revenue growth (6.9% YoY) relative to healthcare sector peers
Heavy insider selling by CFO, COO, and CTO
Long-term value destruction with a 5-year price change of -87.8%
AI Fair Value Estimate
Based on comprehensive analysis
$4.25
+3.9% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
28
Weak
40
50
20
30
0
AI Verdict
High-risk speculative play with poor fundamentals
Key drivers: Piotroski F-Score, Insider Selling, Negative Profitability, High Liquidity
Confidence
90%
Value
40/100
Graham Number N/A due to lack of earnings/book value stability
Positives
- P/S ratio of 2.86 is reasonable for medical devices
Watchpoints
- No P/E due to losses
- P/B of 3.42 is high for a non-profitable entity
Future
50/100
Growth rates are lagging behind sector averages
Positives
- Improving EPS trajectory
- High gross margins provide a path to profitability
Watchpoints
- Low revenue growth (6.9%) suggests limited market penetration
Past
20/100
Historical trend shows consistent failure to maintain value
Positives
- Recent 1Y recovery (+53.8%)
Watchpoints
- Catastrophic 5Y performance (-87.8%)
Health
30/100
Liquidity is the only factor preventing a distress rating
Positives
- Extremely high current and quick ratios
Watchpoints
- Piotroski F-Score of 3/9 (Weak)
Dividend
0/100
Typical for early-stage medical device companies
Positives
No standout positives identified.
Watchpoints
- No dividend paid
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$4.09
Analyst Target
$8.34
Upside/Downside
+103.9%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for SGHT and closest competitors.
Updated 2026-04-17
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
SGHT
Sight Sciences, Inc.
Primary
|
-87.8% | -52.7% | +53.8% | -12.8% | +10.8% | +18.6% |
|
MGNX
MacroGenics, Inc.
Peer
|
-88.9% | -46.5% | +173.2% | +111.6% | +15.7% | +9.1% |
|
CVRX
CVRx, Inc.
Peer
|
-70.1% | -7.4% | -27.5% | -4.1% | +6.5% | -11.5% |
|
RNA
Atrium Therapeutics, Inc.
Peer
|
-2.3% | -2.3% | -2.3% | -2.3% | +17.0% | +13.4% |
|
LUCD
Lucid Diagnostics Inc.
Peer
|
-89.1% | -5.9% | +7.6% | +8.5% | -6.6% | +13.3% |
SGH
Sight Sciences, Inc.
Primary
5Y
-87.8%
3Y
-52.7%
1Y
+53.8%
6M
-12.8%
1M
+10.8%
1W
+18.6%
MGN
MacroGenics, Inc.
Peer
5Y
-88.9%
3Y
-46.5%
1Y
+173.2%
6M
+111.6%
1M
+15.7%
1W
+9.1%
CVR
CVRx, Inc.
Peer
5Y
-70.1%
3Y
-7.4%
1Y
-27.5%
6M
-4.1%
1M
+6.5%
1W
-11.5%
RNA
Atrium Therapeutics, Inc.
Peer
5Y
-2.3%
3Y
-2.3%
1Y
-2.3%
6M
-2.3%
1M
+17.0%
1W
+13.4%
LUC
Lucid Diagnostics Inc.
Peer
5Y
-89.1%
3Y
-5.9%
1Y
+7.6%
6M
+8.5%
1M
-6.6%
1W
+13.3%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-7.35
PEG Ratio
N/A
P/B Ratio
3.42
P/S Ratio
2.86
EV/Revenue
2.19
EV/EBITDA
-5.02
Market Cap
$220.88M
Profitability
Profit margins and return metrics
Profit Margin
-49.67%
Operating Margin
-18.0%
Gross Margin
86.17%
ROE
-50.74%
ROA
-16.61%
Growth
Revenue and earnings growth rates
Revenue Growth
+6.9%
Earnings Growth
N/A
Q/Q Revenue Growth
+6.87%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.64
Moderate
Current Ratio
10.22
Strong
Quick Ratio
9.22
Excellent
Cash/Share
$1.7
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Gross Margin
87.3%
Op. Margin
-18.0%
Net Margin
-20.4%
Total Assets
$0.1B
Liabilities
$0.1B
Equity
$0.1B
Debt/Equity
0.80x
Operating CF
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
91%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-07
$N/A
2026-03-04
$-0.08
+42.9% surprise
2025-11-06
$-0.16
+38.6% surprise
2025-08-07
$-0.23
+16.9% surprise
Healthcare Sector Comparison
Comparing SGHT against 447 companies in the Healthcare sector
(26 bullish, 140 neutral, 281 bearish)
Return on Equity (ROE)
-50.74%
This Stock
vs
-97.42%
Sector Avg
-47.9%
(Below Avg)
Profit Margin
-49.67%
This Stock
vs
-14.95%
Sector Avg
+232.2%
(Superior)
Debt to Equity
0.64
This Stock
vs
3.06
Sector Avg
-79.1%
(Less Debt)
Revenue Growth
6.9%
This Stock
vs
147.85%
Sector Avg
-95.3%
(Slower)
Current Ratio
10.22
This Stock
vs
4.68
Sector Avg
+118.6%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
SGHT
Sight Sciences, Inc.
|
BEARISH | $220.88M | - | -50.7% | -49.7% | $4.09 | |
|
MGNX
MacroGenics, Inc.
|
BEARISH | $220.55M | - | -86.9% | -49.9% | $3.47 | Compare |
|
CVRX
CVRx, Inc.
|
BEARISH | $220.23M | - | -96.6% | -94.1% | $8.37 | Compare |
|
RNA
Atrium Therapeutics, Inc.
|
BEARISH | $223.57M | - | -% | -265.9% | $14.41 | Compare |
|
LUCD
Lucid Diagnostics Inc.
|
BEARISH | $218.06M | - | -710.6% | -% | $1.28 | Compare |
SGHT
Sight Sciences, Inc.
BEARISH
Mkt Cap
$221M
P/E
-
ROE
-50.7%
Price
$4.09
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-06 | HAYDEN JEREMY BRAGG | Officer | Sale | 13,761 | $48,852 |
| 2026-04-06 | RODBERG JAMES | Chief Financial Officer | Sale | 7,231 | $25,670 |
| 2026-04-02 | BADAWI DAVID | Chief Technology Officer | Sale | 8,168 | $28,425 |
| 2026-04-02 | BAUERLEIN ALISON | Chief Operating Officer | Sale | 25,874 | $90,042 |
| 2026-04-01 | TAYLOR BRENTON | Officer | Sale | 2,869 | $10,615 |
| 2026-04-01 | BADAWI PAUL | Chief Executive Officer | Sale | 29,244 | $108,203 |
| 2026-02-19 | BADAWI DAVID | Chief Technology Officer | Option Exercise | 21,270 | $4,892 |
| 2026-02-03 | TAYLOR BRENTON | Officer | Stock Award | 100,464 | - |
| 2026-02-03 | HAYDEN JEREMY BRAGG | Officer | Stock Award | 115,920 | - |
| 2026-02-03 | BADAWI DAVID | Chief Technology Officer | Stock Award | 64,915 | - |
| 2026-02-03 | BADAWI PAUL | Chief Executive Officer | Stock Award | 154,560 | - |
| 2026-02-03 | BAUERLEIN ALISON | Chief Operating Officer | Stock Award | 127,512 | - |
| 2026-02-03 | RODBERG JAMES | Chief Financial Officer | Stock Award | 86,940 | - |
| 2026-01-16 | HAYDEN JEREMY BRAGG | Officer | Sale | 6,308 | $41,759 |
| 2026-01-16 | BADAWI DAVID | Chief Technology Officer | Sale | 4,836 | $32,014 |
HAYDEN JEREMY BRAGG
Officer
2026-04-06
13,761 shares
·
$48,852
RODBERG JAMES
Chief Financial Officer
2026-04-06
7,231 shares
·
$25,670
BADAWI DAVID
Chief Technology Officer
2026-04-02
8,168 shares
·
$28,425
BAUERLEIN ALISON
Chief Operating Officer
2026-04-02
25,874 shares
·
$90,042
TAYLOR BRENTON
Officer
2026-04-01
2,869 shares
·
$10,615
BADAWI PAUL
Chief Executive Officer
2026-04-01
29,244 shares
·
$108,203
BADAWI DAVID
Chief Technology Officer
2026-02-19
21,270 shares
·
$4,892
TAYLOR BRENTON
Officer
2026-02-03
100,464 shares
HAYDEN JEREMY BRAGG
Officer
2026-02-03
115,920 shares
BADAWI DAVID
Chief Technology Officer
2026-02-03
64,915 shares
BADAWI PAUL
Chief Executive Officer
2026-02-03
154,560 shares
BAUERLEIN ALISON
Chief Operating Officer
2026-02-03
127,512 shares
RODBERG JAMES
Chief Financial Officer
2026-02-03
86,940 shares
HAYDEN JEREMY BRAGG
Officer
2026-01-16
6,308 shares
·
$41,759
BADAWI DAVID
Chief Technology Officer
2026-01-16
4,836 shares
·
$32,014
Insider transactions can signal confidence or concerns about company prospects
SEC Filings
Recent regulatory filings from the SEC EDGAR database
8-K
10-K
8-K
8-K
8-K
10-Q
8-K
8-K
8-K
8-K
Data sourced from SEC EDGAR. AI summaries generated automatically.
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
4 analysts
UBS
2026-03-06
Buy
Buy
Citigroup
2026-03-06
Neutral
Neutral
Stifel
2026-03-02
Buy
Buy
Piper Sandler
2026-01-05
Neutral
Overweight
UBS
2025-12-23
Buy
Buy
Citigroup
2025-12-11
Neutral
Neutral
Lake Street
2025-12-10
Buy
Buy
Morgan Stanley
2025-12-02
Equal-Weight
Equal-Weight
Morgan Stanley
2025-11-10
Equal-Weight
Equal-Weight
Piper Sandler
2025-11-07
Neutral
Neutral
Past News Coverage
Recent headlines mentioning SGHT from our newsroom.
Newest → oldest
No matching news yet.